The collaboration among the National Cancer Center Japan, JVCKENWOOD, Sysmex, and Daiichi Sankyo aims to detect cancer-specific exosomes from patients' blood.
The two companies plan to secure required initial regulatory approvals in individual African territories before expanding to other areas in the region.
The subsidiary of Sysmex is evaluating two liquid biopsy technologies for their abilities to monitor patient response to chemotherapy in breast cancer patients.
The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business.
